HB-adMSCs for the Treatment of Crohn's Disease
Hope Biosciences Research Foundation
Abstract
Methodology: Randomized, double-blind, efficacy and safety study of allogeneic HB-adMSCs vs placebo for the treatment of Crohn's Disease with a 16-week treatment period and a safety and efficacy follow up period for 52 weeks post first treatment. Treatment Duration: 16 weeks General Objectives: To assess the efficacy and safety of multiple intravenous infusions of allogeneic HB-adMSCs by improving signs and symptoms of Crohn's Disease in this subject population. Number of Subjects: 46 (23 in each treatment arm) Indication: Crohn's Disease Phase: PHASE2 Status: RECRUITING Conditions: Crohn Disease (CD) Interventions: HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells; 0.9% sodium chloride